Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 January 2022 - 10:30PM
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical
company developing a new class of complement medicines for patients
with classical complement-mediated autoimmune, neurodegenerative
and ophthalmic disorders, today announced that Douglas Love, Esq.,
President & Chief Executive Officer, will present at the 40th
Annual J.P. Morgan Healthcare Conference on Tuesday, January 11,
2022, at 3:45 p.m. ET.
A live webcast of the event can be accessed under the ‘Events
& Presentations’ section on the Investors page at
www.annexonbio.com. A replay of the webcast will be archived on the
Annexon website for 30 days following the presentation.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical
company developing a new class of complement medicines for patients
with classical complement-mediated autoimmune, neurodegenerative,
and ophthalmic disorders of the body, brain, and eye. The company’s
pipeline is based on its platform technology addressing a broad
spectrum of well-researched classical complement-mediated
autoimmune and neurodegenerative diseases triggered by aberrant
activation of C1q, the initiating molecule of the classical
complement pathway. Annexon is advancing a portfolio of innovative
product candidates designed to block the activity of C1q and the
entire classical complement pathway: ANX005 (intravenous
administration), ANX007 (intravitreal administration), and ANX009
(subcutaneous administration). Annexon is deploying a disciplined,
biomarker-driven strategy designed to improve the probability of
technical success of its portfolio. For more information,
visit www.annexonbio.com.
Contact:
Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Mar 2023 to Mar 2024